Last reviewed · How we verify
AFX3772
AFX3772 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.
AFX3772 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation. Used for FGFR-altered solid tumors (Phase 2 development).
At a glance
| Generic name | AFX3772 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | FGFR inhibitor |
| Target | FGFR (Fibroblast Growth Factor Receptor) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AFX3772 targets FGFR pathways implicated in various cancers and fibrotic diseases. By inhibiting FGFR-mediated signaling, the drug aims to suppress proliferation of FGFR-dependent tumor cells and reduce pathological fibroblast activation. This mechanism is particularly relevant in cancers with FGFR alterations and in fibrotic conditions where FGFR signaling drives disease progression.
Approved indications
- FGFR-altered solid tumors (Phase 2 development)
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AFX3772 CI brief — competitive landscape report
- AFX3772 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI